BR112015024626A2 - redução de tamanho da partícula de um composto antimuscarínico - Google Patents
redução de tamanho da partícula de um composto antimuscarínicoInfo
- Publication number
- BR112015024626A2 BR112015024626A2 BR112015024626A BR112015024626A BR112015024626A2 BR 112015024626 A2 BR112015024626 A2 BR 112015024626A2 BR 112015024626 A BR112015024626 A BR 112015024626A BR 112015024626 A BR112015024626 A BR 112015024626A BR 112015024626 A2 BR112015024626 A2 BR 112015024626A2
- Authority
- BR
- Brazil
- Prior art keywords
- particle size
- size reduction
- drug
- antimuscarinic compound
- antimuscarinic
- Prior art date
Links
- 230000001022 anti-muscarinic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000010951 particle size reduction Methods 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 230000002776 aggregation Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000012296 anti-solvent Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
resumo patente de invenção: "redução de tamanho da partícula de um composto antimuscarínico". a presente invenção refere-se a um processo para a preparação de um particulado micronizado cristalino de um sal de glicopirrônio. o processo envolve a suspensão do fármaco em um antissolvente imiscível em água em que o fármaco não tem quase nenhuma solubilidade, e a micronização da suspensão. as partículas de fármaco resultantes são fisicamente estáveis no que diz respeito à aglomeração e/ou agregação sob armazenagem. 1/1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13165483.2 | 2013-04-26 | ||
| EP13165483 | 2013-04-26 | ||
| PCT/EP2014/058295 WO2014173987A1 (en) | 2013-04-26 | 2014-04-24 | Particle size reduction of an antimuscarinic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015024626A2 true BR112015024626A2 (pt) | 2017-07-18 |
| BR112015024626B1 BR112015024626B1 (pt) | 2022-11-01 |
Family
ID=48190260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015024626-5A BR112015024626B1 (pt) | 2013-04-26 | 2014-04-24 | Processo para a preparação de partículas micronizadas de um sal de glicopirrônio farmaceuticamente aceitável |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9393202B2 (pt) |
| EP (2) | EP3574895B1 (pt) |
| JP (1) | JP6449246B2 (pt) |
| KR (1) | KR102198354B1 (pt) |
| CN (1) | CN105120841B (pt) |
| AR (1) | AR096087A1 (pt) |
| AU (1) | AU2014259443B2 (pt) |
| BR (1) | BR112015024626B1 (pt) |
| CA (1) | CA2910314C (pt) |
| DK (2) | DK2988728T3 (pt) |
| ES (2) | ES2754255T3 (pt) |
| FI (1) | FI3574895T3 (pt) |
| HK (1) | HK1216302A1 (pt) |
| HR (2) | HRP20230337T1 (pt) |
| HU (2) | HUE046213T2 (pt) |
| IL (1) | IL242209A (pt) |
| MX (1) | MX365295B (pt) |
| MY (1) | MY169127A (pt) |
| PH (1) | PH12015502449A1 (pt) |
| PL (2) | PL2988728T3 (pt) |
| PT (2) | PT2988728T (pt) |
| RU (1) | RU2667636C2 (pt) |
| SG (1) | SG11201508760VA (pt) |
| SI (2) | SI3574895T1 (pt) |
| TW (1) | TWI630926B (pt) |
| UA (1) | UA120418C2 (pt) |
| WO (1) | WO2014173987A1 (pt) |
| ZA (1) | ZA201507916B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| ES2867552T3 (es) | 2013-07-11 | 2021-10-20 | Chiesi Farm Spa | Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación |
| EA201790832A1 (ru) | 2014-10-16 | 2017-09-29 | Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк. | Ингалируемый состав |
| JP6500522B2 (ja) * | 2015-03-16 | 2019-04-17 | セイコーエプソン株式会社 | 回路装置、物理量検出装置、電子機器及び移動体 |
| ES2789365T3 (es) | 2015-11-16 | 2020-10-26 | Chiesi Farm Spa | Un procedimiento para la preparación de una formulación de polvo seco que comprende un anticolinérgico, un corticoesteroide y un beta-adrenérgico |
| TWI731891B (zh) | 2015-11-16 | 2021-07-01 | 義大利商吉斯藥品公司 | 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法 |
| US9925168B2 (en) * | 2016-01-22 | 2018-03-27 | Chiesi Farmaceutici S.P.A. | Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation |
| JP6323846B2 (ja) * | 2016-04-07 | 2018-05-16 | 塩野義製薬株式会社 | オピオイドを含有する乱用防止製剤 |
| PT109445B (pt) * | 2016-06-08 | 2018-11-06 | Hovione Farm Sa | Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose |
| ES2805434T3 (es) * | 2016-07-29 | 2021-02-12 | Inke Sa | Procedimiento de estabilización de tamaño de partícula |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| HUT70952A (en) * | 1992-06-10 | 1995-11-28 | Eastman Kodak Co | Surface modified nanoparticles based on nosteroidal inflammatory drugs, process for preparing them and pharmaceutical compns. contg. them |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| EP1562551A1 (en) * | 2002-11-18 | 2005-08-17 | E.I. du Pont de Nemours and Company | Media milling using nonspherical grinding media |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| GB0409703D0 (en) * | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| GB0516549D0 (en) | 2005-08-12 | 2005-09-21 | Sulaiman Brian | Milling system |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| BRPI0821186A2 (pt) | 2007-12-13 | 2015-06-16 | Novartis Ag | Compostos orgânicos |
| KR20100095587A (ko) * | 2007-12-13 | 2010-08-31 | 노파르티스 아게 | 유기 화합물 |
| DE102008000482A1 (de) | 2008-03-03 | 2009-09-10 | Zf Friedrichshafen Ag | Ölgekühltes Reibschaltelement |
| EP3090792A1 (en) * | 2008-07-18 | 2016-11-09 | Prosonix Limited | Process for improving crystallinity |
| AU2010253776B2 (en) * | 2009-05-29 | 2015-01-22 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems |
| JP2014504260A (ja) * | 2010-10-15 | 2014-02-20 | グラクソ グループ リミテッド | 集合ナノ粒子状薬物製剤、その製造及び使用 |
| US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
-
2014
- 2014-04-22 US US14/258,147 patent/US9393202B2/en active Active
- 2014-04-24 EP EP19182996.9A patent/EP3574895B1/en active Active
- 2014-04-24 HU HUE14724332A patent/HUE046213T2/hu unknown
- 2014-04-24 CN CN201480022369.0A patent/CN105120841B/zh active Active
- 2014-04-24 HR HRP20230337TT patent/HRP20230337T1/hr unknown
- 2014-04-24 ES ES14724332T patent/ES2754255T3/es active Active
- 2014-04-24 WO PCT/EP2014/058295 patent/WO2014173987A1/en active Application Filing
- 2014-04-24 SI SI201432023T patent/SI3574895T1/sl unknown
- 2014-04-24 PT PT147243323T patent/PT2988728T/pt unknown
- 2014-04-24 AR ARP140101710A patent/AR096087A1/es not_active Application Discontinuation
- 2014-04-24 FI FIEP19182996.9T patent/FI3574895T3/fi active
- 2014-04-24 PT PT191829969T patent/PT3574895T/pt unknown
- 2014-04-24 SG SG11201508760VA patent/SG11201508760VA/en unknown
- 2014-04-24 SI SI201431365T patent/SI2988728T1/sl unknown
- 2014-04-24 KR KR1020157026634A patent/KR102198354B1/ko active IP Right Grant
- 2014-04-24 DK DK14724332T patent/DK2988728T3/da active
- 2014-04-24 RU RU2015145521A patent/RU2667636C2/ru active
- 2014-04-24 PL PL14724332T patent/PL2988728T3/pl unknown
- 2014-04-24 PL PL19182996.9T patent/PL3574895T3/pl unknown
- 2014-04-24 BR BR112015024626-5A patent/BR112015024626B1/pt active IP Right Grant
- 2014-04-24 TW TW103114823A patent/TWI630926B/zh active
- 2014-04-24 MY MYPI2015002624A patent/MY169127A/en unknown
- 2014-04-24 UA UAA201510382A patent/UA120418C2/uk unknown
- 2014-04-24 HU HUE19182996A patent/HUE062002T2/hu unknown
- 2014-04-24 ES ES19182996T patent/ES2943109T3/es active Active
- 2014-04-24 AU AU2014259443A patent/AU2014259443B2/en active Active
- 2014-04-24 JP JP2016509457A patent/JP6449246B2/ja active Active
- 2014-04-24 EP EP14724332.3A patent/EP2988728B1/en active Active
- 2014-04-24 MX MX2015014904A patent/MX365295B/es active IP Right Grant
- 2014-04-24 DK DK19182996.9T patent/DK3574895T3/da active
- 2014-04-24 CA CA2910314A patent/CA2910314C/en active Active
-
2015
- 2015-10-22 IL IL242209A patent/IL242209A/en active IP Right Grant
- 2015-10-23 PH PH12015502449A patent/PH12015502449A1/en unknown
- 2015-10-23 ZA ZA2015/07916A patent/ZA201507916B/en unknown
-
2016
- 2016-06-08 HK HK16104300.9A patent/HK1216302A1/zh unknown
- 2016-06-10 US US15/179,048 patent/US9889094B2/en active Active
-
2019
- 2019-10-17 HR HRP20191882TT patent/HRP20191882T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015024626A2 (pt) | redução de tamanho da partícula de um composto antimuscarínico | |
| BR112015023168A2 (pt) | composições de dicetopiperazina microcristalina e métodos | |
| BR112012013503B8 (pt) | composição de suspensão oftálmica aquosa topicamente administrável, e método para manter sua viscosidade | |
| BR112013018108A2 (pt) | concentrado alimentar gelificado, processo para preparar um concentrado alimentar gelificado e uso de um concentrado alimentar gelificado | |
| AR081677A1 (es) | Metodos y composiciones para la administracion intratecal de iduronato-2-sulfatasa, recipiente, sistema para administracion intratecal | |
| BR112013022788A2 (pt) | "composição farmacêutica compreendendo uma dispersão sólida de 1-(4-benzidrilpiperazin-1-il)-3,3-difenilpropan-1-ona" | |
| PH12016500814A1 (en) | Heteroaryl butanoic acid derivatives | |
| BR112015028278A2 (pt) | processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos | |
| BR112015008740A2 (pt) | microesferas | |
| BR112015028124A2 (pt) | formulação estabilizada de pemetrexed | |
| CO6280502A2 (es) | Una composicion farmaceutica | |
| BR112012014572A2 (pt) | sistema de fechamento para recipientes de soluções oftálmicas | |
| TW200711719A (en) | Use of 2,3-dihydroxynaphthalene-6-sulfonic acid salts as dispersants | |
| WO2015198240A3 (en) | Compositions and methods for long acting proteins | |
| AR090975A1 (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida | |
| BR112015026210A2 (pt) | micro-organismo que tem produtividade de l-triptofano e método para produção de l-triptofano com uso dos mesmos | |
| BR112014031306A2 (pt) | composição farmacêutica e respectivos usos | |
| BR112017009811A2 (pt) | composição e método para a modelagem de cabelo | |
| AR098729A1 (es) | Pasta dental de alta salinidad y viscosidad estable | |
| BR112015010815A2 (pt) | produtos nutricionais líquidos estabilizados que incluem sais de cálcio solúveis | |
| BR112018073667A2 (pt) | cristal de derivado de quinolina | |
| BR112014009408A2 (pt) | métodos e sistemas para processamento de dados de imagem | |
| JP2013227300A5 (pt) | ||
| BR112018014858A2 (pt) | preparo de partículas micronizadas de um composto antimuscarínico por cavitação hidrodinâmica | |
| BR112014031846A2 (pt) | redução do tamanho de partículas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/04/2014, OBSERVADAS AS CONDICOES LEGAIS |